HLP003 shows rapid, durable MADRS improvement in adjunctive MDD phase 2; phase 3 tests intermittent dosing to cut daily pill burden.
Ken Kramer, PhD
Advertisement
Articles by Ken Kramer, PhD
HLP003, a deuterated psilocin agonist, enters phase 3 as an add-on for MDD, aiming to boost SSRI/SNRI response earlier.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia
2
GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness
3
When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression
4
Ethics and AI Use in Medical Practice: American College of Physicians Releases Position Statement
5